Rapid Micro Biosystems announced that Samsung Biologics has selected the Growth Direct platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations. “Samsung Biologics is a leading global contract development and manufacturing organization and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “The Growth Direct(R) improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPID:
- Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
- Rapid Micro Biosystems to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Rapid Micro Biosystems files $200M mixed securities shelf
- Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
